Rome, Nov 9. (Adnkronos Health) – “Developing biotechnologies is a very complex activity, especially if we want the discoveries made in academia to then become real solutions for patients.” This was stated by Fabrizio Greco, president of Assobiotech-Federchimica, during the event “The future of pharmaceutical legislation: a system vision,” organized by Nuove Reti in Rome.
“To understand what we need to do, we must start from where ideas originate, which is from young people who are educated and conduct research. We must therefore begin to think about the areas where we can improve young people’s opportunities for training and research, so that the latter then becomes something concrete and industrializable. I am therefore talking about technology transfer, clinical and productive development, which must be framed within a context of clear rules,” he added.
“To be competitive in this world, which has high added value but also high complexities, we must understand that there is no single solution. All actors involved in this journey, which takes an idea to become a therapy for a patient, must do their part to improve the context in which they operate,” he emphasized. “Only if we manage to connect all these pieces will we also become protagonists in biotechnologies. We must also encourage researchers to look beyond publication and ensure that, from the very beginning of research, the goal is to create something concrete, patent it, and make it a solution for patients.” In this dynamic, “technology transfer centers play a fundamental role. It is therefore necessary to create coordination among technology transfer centers and ensure the possibility of sharing knowledge and ideas. This is certainly a fundamental step for ideas to be advanced into the concrete reality of industry,” he concluded.